Evidence map›Paper›PMID 38200955›Full record

ArticleHealthcare (Basel, Switzerland)2023

Complementary Therapies and Their Association with Problems in Therapeutic Adherence to Conventional Synthetic DMARDs in Rheumatoid Arthritis: A Cross-Sectional Study.

Aline Priscilla Santiago-Garcia, Jorge Ivan Gamez-Nava, Felipe Alexis Avalos-Salgado, Sergio Cerpa-Cruz, Edna Lizeth Amaya-Cabrera, Sergio Gutierrez-Ureña, Cesar Arturo Nava-Valdivia, Sergio Gonzalez-Vazquez, Diana Esperanza Arevalo-Simental, Jose Jorge Gomez-Camarena and 6 more

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Aline Priscilla Santiago-GarciaPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-8710-742X
Jorge Ivan Gamez-NavaPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-0001-3787
Felipe Alexis Avalos-SalgadoPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-5328-4519
Sergio Cerpa-CruzDepartamento de Reumatología, Hospital Civil Fray Antonio Alcalde, Guadalajara 45019, Mexico.ORCID 0000-0002-0755-0289
Edna Lizeth Amaya-CabreraDepartamento de Reumatología, Hospital Civil Fray Antonio Alcalde, Guadalajara 45019, Mexico.ORCID 0009-0001-1519-0156
Sergio Gutierrez-UreñaPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-4797-5572
Cesar Arturo Nava-ValdiviaDepartamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-3562-7033
Sergio Gonzalez-VazquezHospital General Regional 110 Instituto Mexicano del Seguro Social, Guadalajara 44716, Mexico.ORCID 0000-0002-4960-6033
Diana Esperanza Arevalo-SimentalPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-7228-0257
Jose Jorge Gomez-CamarenaPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-4689-0091
Juan Manuel Ponce-GuarnerosPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-5035-3347
Norma Alejandra Rodriguez-JimenezPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-7643-6298
Ana Miriam Saldaña-CruzPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0003-2272-9612
Ernesto German Cardona-MuñozResearch Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0001-7868-667X
Laura Gonzalez-LopezPrograma de Doctorado en Farmacologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.ORCID 0000-0002-6517-6344
Research Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases
Universidad de Guadalajara · MXHospital Civil de Guadalajara · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of complementary therapies is highly prevalent among patients with rheumatoid arthritis (RA). Nevertheless, the use of complementary medicine could involve problems in the following of scientifically accepted treatments. To date, there is limited information regarding the association of nonconventional therapies with problems regarding compliance with the treatment. Therefore, the objective of this study was to identify whether the utilization of complementary therapies is associated with a high risk of problems regarding therapeutic adherence to conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs) in RA patients. A survey was performed with RA patients in an outpatient rheumatology clinic in a university hospital; the use of complementary therapies, as well as their type, was identified. To assess problems with therapeutic adherence, we used the four-item Morisky-Green scale. A comprehensive assessment of clinical and therapeutic characteristics was performed. Univariable and multivariable models were performed to identify the risk of problems with therapeutic adherence in users of complementary therapies. In total, 250 RA patients were included; 92% used complementary therapies. Of them, the most frequently used were herbal medicine (65%), homeopathy (64%), and cannabis and its derivatives (51%). In the univariable logistic regression analysis, the factors associated with problems in the therapeutic adherence to cs-DMARDs were age (

Indexed as

complementary therapiesconventional synthetic disease modifying anti-rheumatic drugscross-sectional studyMorisky–Green scalerheumatoid arthritistherapeutic adherences

Identifiers

PMID38200955
PMCPMC10779410
OpenAlexW4390236367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.